At the moment only 5% of patients live that long, and each year in the UK 8,800 people die of the disease
A drug combination which can help pancreatic cancer sufferers survive for at least five years has been hailed as a breakthrough.
Currently, 5% of patients expect to live that long and a mere 1% are still alive 10 years after diagnosis. Survival rates have improved little since the early 1970s.
But a trial, published in the Lancet medical journal, found when chemo drugs gemcitabine and capecitabine were used together in post-op treatment, 29% lived at least five years – compared with 16% on gemcitabine alone.pancreatic cancer ag
The treatment protocol should now become the new standard of care for patients who have had surgery, experts said.